VYNE Therapeutics (VYNE) Stock Price, News & Analysis

Company Overview

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Key Stats

• Today's Range: $1.26 to $1.33
• 50-Day Range: $1.30 to $2.39
• 52-Week Range: $1.26 to $4.30
• Volume: 81,015 shs
• Average Volume: 98,293 shs
• Market Capitalization: $19.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Buy

VYNE Therapeutics Stock Analysis - MarketRank™

VYNE Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 463rd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

VYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of VYNE Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VYNE Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VYNE Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.51% of the float of VYNE Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VYNE Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VYNE Therapeutics has recently increased by 40.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VYNE Therapeutics does not currently pay a dividend.

Dividend Growth

VYNE Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.51% of the float of VYNE Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VYNE Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VYNE Therapeutics has recently increased by 40.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.17

News Sentiment

VYNE Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for VYNE Therapeutics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for VYNE on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of VYNE Therapeutics is held by insiders.

Percentage Held by Institutions

83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VYNE Stock Analysis - Frequently Asked Questions

How have VYNE shares performed this year?

VYNE Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, VYNE stock has decreased by 61.2% and is now trading at $1.30.
View the best growth stocks for 2025 here.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. The company earned $0.20 million during the quarter, compared to analysts' expectations of $0.05 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative trailing twelve-month return on equity of 43.73%.

When did VYNE Therapeutics' stock split?

VYNE Therapeutics shares reverse split on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' top institutional shareholders include XTX Topco Ltd (0.22%). Insiders that own company stock include Patrick G Lepore and Mutya Harsch.
View institutional ownership trends.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VYNE
• CIK: 1566044
• Web: vynetherapeutics.com
• Phone: (800) 755-7936
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.25
• High Stock Price Target: $8.00
• Low Stock Price Target: $4.50
• Potential Upside/Downside: +380.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,450,000.00
• Net Margins: -6,896.55%
• Pretax Margin: -6,885.19%
• Return on Equity: -43.73%
• Return on Assets: -38.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: $501,000.00
• Price / Sales: 39.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.36 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 15,210,000
• Free Float: 14,043,000
• Market Cap: $19.77 million
• Optionable: Not Optionable
• Beta: 1.76